コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ceptor as METx was not expected to cross the blood brain barrier.
2 bility of NPs to be formulated and cross the blood brain barrier.
3 tion attenuated CA/CPR-induced disruption of blood brain barrier.
4 on Day 3 to cause a temporary breach in the blood brain barrier.
5 well as their enhanced transport across the blood brain barrier.
6 e that ultrasmall nanoparticle can cross the blood brain barrier.
7 ncluding the vascular system, lungs, gut and blood-brain barrier.
8 ic profile, and the ability to penetrate the blood-brain barrier.
9 levels to the brain tumour is limited by the blood-brain barrier.
10 rs, such as the blood-testis barrier and the blood-brain barrier.
11 on, and new tissue organizations such as the blood-brain barrier.
12 arge biologics across the highly restrictive blood-brain barrier.
13 ines and an increase the permeability of the blood-brain barrier.
14 o leptin because of poor permeability of the blood-brain barrier.
15 activity due to its ability to penetrate the blood-brain barrier.
16 membrane tight junction proteins forming the blood-brain barrier.
17 ace between the brain and the periphery, the blood-brain barrier.
18 -glycoprotein expression and activity at the blood-brain barrier.
19 er in microvascular endothelial cells of the blood-brain barrier.
20 leterious calcium-dependent breakdown of the blood-brain barrier.
21 d the duration of permeability change in the blood-brain barrier.
22 CP2 variants across an in vitro model of the blood-brain barrier.
23 tion across endothelial barriers such as the blood-brain barrier.
24 surprisingly dispensable for maintaining the blood-brain barrier.
25 nity for locoregional therapy, bypassing the blood-brain barrier.
26 e ortholog Mfsd7c as a gene expressed in the blood-brain barrier.
27 m the basement membrane across a compromised blood-brain barrier.
28 n cognition and a higher permeability of the blood-brain barrier.
29 ribed by limited or uneven disruption of the blood-brain barrier.
30 ke in vivo, and efficient passage across the blood-brain barrier.
33 hatases Xpp1, Ssu72, Siw14, and Sit4 promote blood-brain barrier adhesion and crossing by C. neoforma
34 importance, multiple barriers, including the blood brain barrier and the blood cerebrospinal fluid ba
35 nel of different GPCRs, is able to cross the blood-brain barrier and acts as slowly diffusing and ins
36 ks vascular inflammation to breakdown of the blood-brain barrier and blood-cerebrospinal fluid barrie
37 intestine, liver, kidney, heart, lung, skin, blood-brain barrier and brain) for 3 weeks in culture wh
39 flammatory factors and viruses may cross the blood-brain barrier and enter the central nervous system
40 , suggesting a potential role for ILA in the blood-brain barrier and facilitating communication among
41 all superparamagnetic iron oxide crosses the blood-brain barrier and improves lesion visualization wi
42 odegradable polymer implant can overcome the blood-brain barrier and increase the range of drugs avai
43 during exercise by the muscles, crosses the blood-brain barrier and induces Bdnf expression and TRKB
44 human brain sections, that LCN2 crosses the blood-brain barrier and localizes to the hypothalamus in
45 temic levels of free heme, which damages the blood-brain barrier and neurons in distinct regions of t
46 c PreImplantation Factor (sPIF), crosses the blood-brain barrier and prevents neuro-inflammation.
47 tes that ADLumin-1 can efficiently cross the blood-brain barrier and provides excellent contrast for
48 xorubicin (3) could permeabilize an in vitro blood-brain barrier and showed a marked reduction in cyt
49 Previously, Emapunil was shown to cross the blood-brain barrier and to be safe and well tolerated in
50 porting leukocyte transmigration through the blood-brain barrier and, therefore, represents a potenti
51 r advanced glycation-end products, cross the blood-brain-barrier and reach neurons and microglial cel
52 cokinetic studies showed that 4c crosses the blood brain barrier, and in vivo studies demonstrated th
53 ronal network connectivity, hypoxia, altered blood-brain barrier, and neurocellular degeneration.
54 rebral collateral blood flow, stabilised the blood-brain barrier, and reduced infarct size, in precli
55 on, which should prevent the crossing of the blood-brain barrier, and the high M(3)/M(2) selectivity,
56 istered perioperatively, would not cross the blood-brain barrier, and would fluoresce in the near-inf
57 s occurred within brain areas and across the blood-brain barrier; and (d) that migration was associat
58 ngs establish brain endothelial VCAM1 at the blood-brain barrier as a possible target to treat age-re
59 s of mesenchymal stromal cell therapy on the blood-brain barrier, astrocyte activation, neuroinflamma
60 Cocaine use is associated with breach in the blood brain barrier (BBB) and increased HIV-1 neuro-inva
61 ty of hyperpolarized (13)C-AcAc to cross the blood brain barrier (BBB) and its potential to monitor b
62 athological events following TBI, leading to blood brain barrier (BBB) dysfunction, neuronal damage a
65 ctive effect was not due to early changes in blood brain barrier (BBB) permeability, microglia activa
66 ysbiosis lead to permeability changes in the blood brain barrier (BBB), which may eventually result i
71 tro that functional expression of RFC at the blood-brain barrier (BBB) and its upregulation by the vi
72 nce that this is due to the breakdown of the blood-brain barrier (BBB) and that a unique pharmacologi
74 ocytes from the nose into the brain, causing blood-brain barrier (BBB) breakdown, extravasation of au
75 ome (RCVS) with (n = 92) or without (n = 90) blood-brain barrier (BBB) disruption and a diseased cont
76 of nitric oxide synthase (NOS) in mediating blood-brain barrier (BBB) disruption and peripheral immu
80 vous system (CNS) and is often implicated in blood-brain barrier (BBB) dysfunction, but whether and h
81 inhibit aggregation of Abeta42 and cross the blood-brain barrier (BBB) following intravenous administ
82 bral amyloid angiopathy (CAA), which impairs blood-brain barrier (BBB) function and accelerates cogni
83 ndering the development of robust assays for blood-brain barrier (BBB) function, including drug perme
85 artially because the low permeability of the blood-brain barrier (BBB) hinders the release of tumor b
87 lysaccharide (LPS) selectively disrupted the blood-brain barrier (BBB) in Podxl (DeltaTie2Cre) mice.
88 ber 1, ABCB1) plays an important role at the blood-brain barrier (BBB) in promoting clearance of neur
89 otein (ABCB1) plays an important role at the blood-brain barrier (BBB) in promoting the clearance of
91 Serum and CSF biomarkers of inflammation and blood-brain barrier (BBB) integrity were measured preope
94 studies have suggested that breakdown of the blood-brain barrier (BBB) is an early biomarker of human
98 quently, regulation of manganese flux at the blood-brain barrier (BBB) is critical to brain homeostas
106 nduced pluripotent stem cell (hiPSC)-derived blood-brain barrier (BBB) models established to date lac
107 ral nervous system (CNS) induces endothelial blood-brain barrier (BBB) opening as well as the formati
109 adoption of focused ultrasound (FUS)-induced blood-brain barrier (BBB) opening, both to ensure safe a
110 followed by multiple unilateral FUS-induced blood-brain barrier (BBB) openings in the left basal gan
112 sone) could overcome these difficulties, but blood-brain barrier (BBB) penetration of related drugs i
123 the central nervous system (CNS) through the blood-brain barrier (BBB) remains poorly understood.
124 nsulin resistance.SIGNIFICANCE STATEMENT The blood-brain barrier (BBB) restricts the entry of circula
126 Among all these biological barriers, the blood-brain barrier (BBB) strongly impede hurdle for dru
127 eatment, however, remains constrained by the blood-brain barrier (BBB) that impedes the access of mos
128 tem (CNS) blood vessels contain a functional blood-brain barrier (BBB) that is necessary for neuronal
131 rain, which the virus enters by crossing the blood-brain barrier (BBB) via macrophages, which are con
133 hat CCR2-RFP monocytes were recruited to the blood-brain barrier (BBB) within 2 wk of T. gondii infec
134 report that pharmacologic restoration of the blood-brain barrier (BBB), 12 mo after murine TBI, is as
135 the cellular and molecular components of the blood-brain barrier (BBB), a specialized neurovascular u
136 frequently compromises the integrity of the blood-brain barrier (BBB), and infects the CNS in the ea
137 However, lysosomal enzymes do not cross the blood-brain barrier (BBB), and intravenous enzyme infusi
138 ace often exist behind a functionally intact blood-brain barrier (BBB), and so are shielded from expo
139 MENT Although rarely expressed at the normal blood-brain barrier (BBB), claudin-1 is expressed in pat
140 y astrocytosis, microgliosis, erosion of the blood-brain barrier (BBB), formation of inflammatory cyt
141 moting high-resistance barriers, such as the blood-brain barrier (BBB), have not yet been fully defin
142 ascular interface of the brain, known as the blood-brain barrier (BBB), is understood to maintain bra
143 esentative AAV8, are capable of crossing the blood-brain barrier (BBB), thereby enabling the delivery
144 of chemotherapy or immunotherapy through the blood-brain barrier (BBB), together with the brain's uni
145 used exclusively to transiently disrupt the blood-brain barrier (BBB), which may induce a sterile in
146 gnificantly hindered by the existence of the blood-brain barrier (BBB), which serves as a protective
147 ve a series of unique properties, termed the blood-brain barrier (BBB), which stringently regulate th
148 ansparent model organism with an endothelial blood-brain barrier (BBB), zebrafish offer a powerful to
170 cells (microglia and macrophages); increased Blood-Brain-Barrier (BBB)-disruption; decreased levels o
171 ysfunction (particularly at the level of the blood-brain barrier [BBB]) contributes to stroke pathoge
172 lizing effects in the blood circulation, the blood-brain barrier/blood-brain tumor barrier (BBB/BBTB)
175 udy sheds new light on the mechanisms behind blood-brain barrier breakdown in this complicated neurol
176 F B cells were associated with inflammation, blood-brain barrier breakdown, and intrathecal Ig synthe
177 stic studies indicated that I-S1 crosses the blood-brain barrier by adsorptive transcytosis and that
178 rated that drugs can be delivered across the blood-brain barrier by exposing circulating microbubbles
179 PORTANCE Understanding how viruses cross the blood-brain barrier can provide insight into new approac
181 l experiments using an in vitro model of the blood-brain barrier confirmed that kynurenine competes w
182 rance processes, including the generation of blood-brain barrier-crossing metabolic products crucial
183 vates secondary brain injury by exacerbating blood-brain barrier damage, microvascular failure, brain
185 that intranasal administration bypasses the blood-brain barrier, delivering oxytocin to specific bra
186 that satisfy the structural requirements of blood-brain barrier diffusion and FAAH substrate recogni
187 ry, including receptor-targeted, cell-based, blood-brain-barrier disrupting and MRI-guided focused ul
188 g in the CECs, which is known to lead to the blood-brain barrier disruption and allow peripheral cyto
189 re protected against indoxyl sulfate-induced blood-brain barrier disruption and cognitive impairment.
190 by indoxyl sulfate, a uremic toxin, leads to blood-brain barrier disruption associated with cognitive
191 ologic deficits by neurobehavioral tests and blood-brain barrier disruption by SPECT/CT imaging after
195 sulfate fragments penetrated the hippocampal blood-brain barrier during sepsis and inhibited BDNF-med
196 cco in vascular disease and implications for blood-brain barrier dysfunction and cognitive decline.
198 ls; (ii) innate immune activation; and (iii) blood-brain barrier dysfunction with low BACE1 levels.
199 erformed, angiopoietin-2 was associated with blood-brain barrier dysfunction, and markers of neuroinf
200 wn to ameliorate Plasmodium parasite growth, blood-brain barrier dysfunction, and mortality in a mous
201 d behavioral alterations, as well as reduced blood-brain barrier dysfunction, astrocyte activation, a
202 ogy in Tg-SwDI mice as observed by increased blood-brain barrier dysfunction, loss of tight junction
204 d compound was demonstrated to penetrate the blood-brain barrier, elevate levels of methylglyoxal in
205 mity of the oral cavity to the brain and the blood brain barrier enhances the interest to study this
206 with brain endothelial cells and astrocytes, blood-brain barrier extravasation, angiogenesis, and out
208 29 appears to more readily cross an immature blood-brain barrier following systemic administration, s
209 ry of iron oxide based substances across the blood-brain barrier for targeting, imaging and therapy o
210 t of DEG, underscoring PVEC's implication in blood-brain barrier formation and maintenance of nutrien
212 synapse formation and synaptic transmission, blood-brain barrier formation, and regulation of blood f
215 DARs expressed on endothelial cells regulate blood-brain barrier function via myosin light chain phos
216 emic brain, endothelial cell S1P(1) supports blood-brain barrier function, microvascular patency, and
217 ductions in cerebral blood flow and impaired blood-brain barrier function, which are leading contribu
219 e we describe a glucosamine-coated NISV, for blood-brain barrier GLUT1 targeting, capable of traversi
220 and corresponding difficulty in crossing the blood-brain barrier has limited development in this area
222 radioiodinated S1 (I-S1) readily crossed the blood-brain barrier in male mice, was taken up by brain
223 ulin into cerebrospinal fluid and across the blood-brain barrier in some brain regions increased, alt
225 ctivated in major cellular components of the blood-brain barrier, including endothelial cells and ast
226 nhibitor that does not efficiently cross the blood-brain barrier, induced gastroparesis only at signi
227 ishing an antiviral state, but also promotes blood brain barrier integrity, adaptive immunity, and ac
228 gents that are sensitive to the reduction in blood-brain barrier integrity associated with inflammati
229 CP) following neonatal stroke in relation to blood-brain barrier integrity, injury, microglial activa
230 , mesenchymal stromal cell therapy protected blood-brain barrier integrity, reduced astrogliosis and
234 lls and astrocytic endfeet that comprise the blood-brain barrier is rich in collagen, laminin, agrin,
236 rugs across biological barriers, such as the blood-brain barrier, is often a limiting factor in achie
237 lesions exacerbates inflammatory responses, blood-brain barrier leakage (BBB), and cognitive deficit
238 disease featuring elevated IFN-gamma levels, blood-brain barrier leakage, and/or T cell infiltration,
239 play important roles in vascular formation, blood-brain barrier maintenance, and regulation of regio
240 atients with brain pathologies involving the blood-brain barrier, namely malignant brain tumours, isc
241 systemic circulation translocate across the blood brain barrier of zebrafish larvae and sequester in
243 al (IA) infusion of mannitol induces osmotic blood-brain barrier opening (OBBBO) and that method has
244 amyloid transmissibility among cells of the blood-brain barrier or access the brain in other ways.
245 s/EVs have an intrinsic ability to cross the blood-brain-barrier, our technology may provide a new ap
246 GES-1), the enzyme generating PGE2, prevents blood-brain barrier P-gp up-regulation after status epil
247 icensed drugs with evidence of human safety, blood-brain barrier penetrance and demonstrable efficacy
250 ment of the endothelial receptor pool with a blood-brain barrier penetrating S1P(1)-selective agonist
252 The targeted Ang-3I-NM@siRNA exhibits superb blood-brain barrier penetration and potent tumor accumul
253 the limited bioavailability, poor cell, and blood-brain barrier penetration, and low drug half-life
254 ing affinity and lipophilicity for favorable blood-brain barrier penetration, while the use of optimi
258 Overall, recent evidence indicates that blood-brain barrier pericytes can be a previously unreco
259 Importantly, recent research indicates that blood-brain barrier pericytes can be a target of HIV-1 i
262 of action (covalents, PROTACs), increases in blood-brain barrier permeability (BBBP), and the targeti
263 s one of the rare TLR4 antagonists with good blood-brain barrier permeability and showing no stereose
264 emic inflammation and normalized compromised blood-brain barrier permeability and tight junction prot
265 , and social memory tests and an increase of blood-brain barrier permeability associated with renal d
267 n STAT1 also developed severe hydrocephalus, blood-brain barrier permeability, and increased brain in
268 city, pharmacokinetics, metabolic stability, blood-brain barrier permeability, and off-target binding
269 n neonatal mice of both sexes in relation to blood-brain barrier permeability, injury, microglial act
270 These effects may be related to increased blood-brain barrier permeability, with altered tight-jun
275 NFIA-deficient astrocytes exhibit defects in blood-brain barrier remodeling, which are correlated wit
276 partial restoration of the integrity of the blood-brain barrier, respectively; similar to results ob
277 sistance; however, GBM's location behind the blood-brain barrier severely limits chemotherapeutic opt
278 cial membrane permeability assay (PAMPA) and blood-brain barrier-specific PAMPA, and therefore might
279 thnicity, and cognitive reserve, SNPs in the blood-brain barrier, telomere homeostasis, and DNA repai
280 ds that are absorbed in the gut or cross the blood brain barrier through endogenous transporters.
281 less permeable than naloxone-HCl across the blood-brain barrier, thus acting as a selective blocker
282 the goal of normalizing the integrity of the blood-brain barrier, thus benefiting numerous brain path
284 inated through the circulation and cross the blood-brain barrier to access the brain, initiate feed-f
285 ecently proposed technique that bypasses the blood-brain barrier to achieve noninvasive and localized
286 ormone secreted by adipocytes, can cross the blood-brain barrier to act on neurons in different brain
287 ociated virus vector serotypes can cross the blood-brain barrier to deliver a gene into the CNS.
289 Canx dictates the permeability of the model blood-brain barrier to immune cells and is also a prereq
291 E pathogenesis and on the patency of a model blood-brain barrier to T-cell transcellular migration.
292 in all areas of the CNS without breaking the blood-brain barrier, to monitor gene and cell therapy.
293 ogether with the ability of EVs to cross the blood-brain barrier undeterred and through the exploitat
295 r anomalies and brain tissue infarction, the blood-brain barrier was maintained in Flvcr2 mutant mice
296 ib, a proteasome inhibitor able to cross the blood-brain barrier, we found that it modulates the meta
298 ly expressed within endothelial cells of the blood-brain barrier where removal in conditional mice le
299 hysicochemical properties for permeating the blood-brain barrier, while others contain problematic st
300 glucosamine vesicle transcytosis across the blood-brain barrier with intact cargo, which is partiall